Washington, DC CNN —The US economy is set to reap considerable benefits from Americans taking popular medications used for weight loss, including Ozempic and Wegovy, Goldman Sachs analysts wrote in a recent research report.
Originally developed to treat type 2 diabetes, they proved to be highly effective at helping people shed weight in clinical trials.
(Ozempic has not been approved for weight loss by regulators, though Wegovy, a similar drug, has.)
Goldman Sachs argues that since poor health unambiguously weighs on the economy, improving health outcomes due to GLP-1s could lower costs and boost productivity, shoring up economic output.
For some Americans who are obese but don’t have diabetes, obtaining those drugs has become difficult, if not impossible.
Persons:
Goldman Sachs, Eli Lilly, Jody Dushay, Beth, Doug Langa, they’ve
Organizations:
DC CNN, Government, Novo Nordisk, Beth Israel Deaconess Medical, CNN
Locations:
Washington, United States, North America, Novo